Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
Abstract Blockade of PD-1/PD-L1 interactions is proving an exciting, durable therapeutic modality in a range of cancers whereby T cells are released from checkpoint inhibition to revive their inherent anti-tumour activity. Here we have studied various ways to model ex vivo T cell function in order t...
Guardado en:
Autores principales: | Alexander Roberts, Lindsay Bentley, Tina Tang, Fay Stewart, Chiara Pallini, Joel Juvvanapudi, Graham R. Wallace, Alison J. Cooper, Aaron Scott, David Thickett, Sebastian T. Lugg, Hollie Bancroft, Bridget Hemming, Charlotte Ferris, Gerald Langman, Andrew Robinson, Joanne Chapman, Babu Naidu, Thomas Pinkney, Graham S. Taylor, Kristian Brock, Zania Stamataki, Catherine A. Brady, S. John Curnow, John Gordon, Omar Qureshi, Nicholas M. Barnes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/17d4c012af55407c96c408b8c553e796 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion
por: David H. Peng, et al.
Publicado: (2020) -
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017) -
Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015) -
Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021) -
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Zhitao Li, et al.
Publicado: (2021)